News Releases

News Release

Meridian Bioscience Receives FDA Clearance for New E. coli Test

February 20, 2007 at 9:48 AM EST

Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard STAT!® EHEC, a revolutionary new test for the diagnosis of E. coli infection. The new product detects all Shiga-toxin producing E. coli and is the first rapid (20 minute) E. coli diagnostic that differentiates between Toxin 1 & Toxin 2.

With the recent national E. coli outbreaks (spinach in September 2006 and lettuce in December 2006), there has been an increased need in the hospital market for a highly accurate, quick, easy-to-use E. coli test. New CDC recommendations published in September 2006 recommend that laboratories use a test that detects all Shiga-toxin producing E. coli, not just a test that detects the O157 E. coli strain. ImmunoCard STAT!® EHEC, with its easy-to-perform procedure, provides a practical solution that will enable laboratories to adopt those new CDC recommendations.

ImmunoCard STAT!® EHEC is the first product resulting from a strategic partnership that was announced in August 2006 with the Performance & Life Science Chemicals Division of Merck KGaA, Darmstadt, Germany and its American company EMD. This new-to-the-world product introduction demonstrates the value of the long-term strategic partnership that has been formed.

John A. Kraeutler, President and Chief Operating Officer, stated, “Disease caused by E. coli can be devastating, particularly with children, and Meridian is proud to introduce an advanced method for rapid E. coli testing that will significantly improve patient care. The launch of ImmunoCard STAT!® EHEC further solidifies Meridian's position as a leader in the field of E. coli testing.”

FORWARD LOOKING STATEMENTS The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements which may be identified by words such as “estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update any forward-looking statements. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Costs and difficulties in complying with laws and regulations administered by the United States Food and Drug Administration can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. Changes in the relative strength or weakness of the U.S. dollar can change expected results. One of Meridian's main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses successfully integrated into Meridian's operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list of uncertainties and risks that may affect the financial performance of the Company.

Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company's shares are traded through NASDAQ's Global Select Market, symbol VIVO. Meridian's website address is

CONTACT: Meridian Bioscience, Inc.
John A. Kraeutler, President, 513-271-3700

SOURCE: Meridian Bioscience, Inc.